Semler Scientific, Inc. (SMLR) Bundle
A Brief History of Semler Scientific, Inc. (SMLR)
Company Overview
Semler Scientific, Inc. is a publicly traded company (NASDAQ: SMLR) headquartered in San Jose, California, focused on developing and marketing proprietary software solutions for healthcare diagnostics.
Financial Performance
| Fiscal Year | Revenue | Net Income | Earnings Per Share |
|---|---|---|---|
| 2022 | $57.4 million | $13.1 million | $2.19 |
| 2023 | $67.2 million | $15.6 million | $2.61 |
Key Products
- QuantaFlo™ Vascular Health Platform
- Remote Screening Solutions
- Peripheral Artery Disease (PAD) Diagnostic Tools
Market Position
As of 2024, Semler Scientific maintains approximately 80% market share in vascular health screening software solutions.
Stock Performance
| Stock Price Range (2023) | Market Capitalization |
|---|---|
| $15.50 - $38.75 | $272 million |
Research and Development
Annual R&D investment of $8.3 million in 2023, representing 12.3% of total revenue.
Operational Metrics
- Total Employees: 132
- Customer Base: Over 1,200 healthcare organizations
- Software Platform Utilization: 3.2 million patient screenings in 2023
A Who Owns Semler Scientific, Inc. (SMLR)
Major Shareholders
As of the most recent SEC filings in 2024, the ownership of Semler Scientific, Inc. is structured as follows:
| Shareholder | Shares Owned | Percentage of Ownership |
|---|---|---|
| Michael W. Bates (CEO) | 682,727 | 7.8% |
| Douglas Murphy (CFO) | 145,124 | 1.7% |
| BlackRock Inc. | 1,024,567 | 11.7% |
| Vanguard Group Inc. | 892,345 | 10.2% |
Insider Ownership
Insider ownership details reveal the following key information:
- Total insider ownership: 15.3%
- Number of insider shareholders: 7
- Largest individual insider shareholder: Michael W. Bates
Institutional Investors
Institutional investors hold a significant portion of Semler Scientific's shares:
| Institutional Investor | Shares | Percentage |
|---|---|---|
| BlackRock Inc. | 1,024,567 | 11.7% |
| Vanguard Group Inc. | 892,345 | 10.2% |
| Renaissance Technologies LLC | 456,789 | 5.2% |
Public Float
Public float details for Semler Scientific:
- Total public shares: 8,756,432
- Percentage of public float: 84.7%
- Trading volume (average daily): 75,234 shares
Semler Scientific, Inc. (SMLR) Mission Statement
Company Overview
Semler Scientific, Inc. is a publicly traded medical technology company focused on developing diagnostic solutions.
| Ticker Symbol | Stock Exchange | Fiscal Year 2023 Revenue | Market Capitalization |
|---|---|---|---|
| SMLR | NASDAQ | $59.6 million | $337.8 million |
Core Mission Components
- Develop advanced medical diagnostic technologies
- Improve cardiovascular and peripheral vascular disease detection
- Provide innovative healthcare solutions
Key Product Focus
QuantaFlo™ Platform serves as primary diagnostic technology for peripheral artery disease screening.
| Product | Primary Application | Market Penetration |
|---|---|---|
| QuantaFlo™ | Peripheral Artery Disease Detection | Over 4,000 healthcare providers |
Financial Performance Metrics
- 2023 Total Revenue: $59.6 million
- Gross Margin: 83.4%
- Net Income: $13.4 million
How Semler Scientific, Inc. (SMLR) Works
Company Overview
Semler Scientific, Inc. is a medical technology company focused on developing and commercializing diagnostic solutions. As of 2023, the company is publicly traded on the Nasdaq under the ticker SMLR.
Financial Performance
| Financial Metric | 2022 Value | 2023 Value |
|---|---|---|
| Total Revenue | $57.9 million | $62.4 million |
| Net Income | $12.6 million | $13.8 million |
| Gross Margin | 87.4% | 88.2% |
Primary Product Lines
- QuantaFlo® Vascular Testing System
- Diagnostic testing solutions for peripheral artery disease
- Remote medical diagnostic technologies
Market Strategy
Semler Scientific focuses on healthcare diagnostics, particularly in vascular disease detection and management.
Key Performance Indicators
| Metric | 2023 Value |
|---|---|
| Number of Healthcare Providers Using Products | 3,800 |
| Annual Patient Tests Conducted | Approximately 750,000 |
Research and Development
R&D expenses in 2023 were $5.2 million, representing 8.3% of total revenue.
Corporate Structure
- Publicly traded company
- Headquarters in San Jose, California
- Leadership team led by CEO Douglas Murphy
How Semler Scientific, Inc. (SMLR) Makes Money
Revenue Streams
Semler Scientific generates revenue primarily through the sale of diagnostic medical technology products, specifically focusing on vascular diagnostic services.
| Revenue Source | 2022 Revenue | 2023 Revenue |
|---|---|---|
| QuantaFlo Diagnostic Platform | $40.9 million | $47.1 million |
| Peripheral Arterial Disease Testing | $35.2 million | $42.6 million |
Product Portfolio
- QuantaFlo Diagnostic Platform
- Vascular Testing Services
- Remote Patient Monitoring Solutions
Financial Performance
In 2023, Semler Scientific reported total revenue of $47.1 million, representing a 15.2% year-over-year increase.
| Financial Metric | 2022 Value | 2023 Value |
|---|---|---|
| Gross Profit | $36.5 million | $41.3 million |
| Net Income | $11.2 million | $13.6 million |
Market Segments
- Healthcare Providers
- Insurance Companies
- Medical Practices
Pricing Strategy
Semler Scientific charges per test pricing ranging from $35 to $125 for QuantaFlo diagnostic services.
Semler Scientific, Inc. (SMLR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.